MetaCap

Legend Biotech Corporation ADR (LEGN)

NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.25-0.85 (-5.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LEGN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.02
52-week range
15.15 – 37.50
Day range
15.15 – 16.11
Volume / Avg
3.42M / 2.26M
Beta
—

52-week range

$15.15$37.50

LEGN stock today

Legend Biotech (LEGN) closed at $15.25 on Nov 20, down 5.28% (-$0.85), versus the S&P 500's 3.70% decline. At this level, LEGN sits near the bottom of its 52-week range of $15.15 to $37.50: 59.3% below the high, set on Jun 3, 2026 and 0.7% above the low. LEGN is down 29.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.9%.

Legend Biotech has posted a net loss over the last twelve months (EPS of -$0.02), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Legend Biotech

Company profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Ingrid Zhang
Headquarters
Somerset, NJ
Employees
3,300
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Legend Biotech generated $1.03 billion in revenue, up 64.0% from fiscal 2024, its 4th consecutive year of revenue growth. Legend Biotech reported a net loss of $296.8 million, compared with a loss of $177.0 million a year earlier. Gross margin was 61.4% (down from 65.5%) and operating margin -13.3%.

Legend Biotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.03B$627.24M$285.14M$117.00M$68.83M
Growth+64.04%+119.97%+143.70%+70.00%-8.23%
Net income$-296.80M$-177.03M$-518.25M$-446.35M$-403.58M
EPS (diluted)$-0.81$-0.48$-1.47$-1.40$-1.43

Analyst forecast

Forecast

Consensus (14 analysts)

buy

Avg. price target

$40.93+168.39%

  • Strong buy 5
  • Buy 3
  • Hold 6
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.11 vs $0.01
Surprise
-1200.00%

LEGN news

All LEGN news

Legend Biotech peers

Health Care sector
LEGN peer companies
CompanyPrice% ChgMarket capCompare
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs LEGN
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs LEGN
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs LEGN
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs LEGN
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs LEGN
SLSSELLAS Life Sciences Group Inc.13.66-8.08%$2.78Bvs LEGN
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs LEGN
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs LEGN

Indexes, lists and sector

Legend Biotech stock FAQ

What is Legend Biotech's stock price today?

LEGN last traded at $15.25 as of Nov 20, 4:00 PM EST, down 5.28% on the day. Prices are delayed at least 15 minutes.

Who is Legend Biotech's CEO?

Ms. Ingrid Zhang is the chief executive officer of Legend Biotech Corporation ADR, which has about 3,300 employees.

What is the LEGN 52-week high?

The 52-week high for LEGN is $37.50 and the 52-week low is $15.15. The stock is currently 59.3% below its high.

Compare LEGN